TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07899073: A Multicenter, Randomized, Double-blind, Phase Ⅲ Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients

Sponsor: Hanmi Pharmaceutical Company Limited · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 225 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07899073 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07899073 Rescue Dossier →